The Shoemaker Protocol for CIRS, Explained (2026 Clinical Read)

Dr. Ritchie Shoemaker did something nobody in environmental medicine had done before: he made mold illness measurable. Before his work, "I think my house is making me sick" was a conversation that ended at the door of most physicians' offices. After it, there was a lab panel, a genotype, a visual test, and a step sequence you could audit.

That's why the protocol still matters in 2026, and why we use its spine in our own clinic — even though we don't run it exactly as published.

What CIRS actually is

Chronic Inflammatory Response Syndrome is an innate immune system that never stands down.

In roughly three-quarters of people, biotoxins from water-damaged buildings get tagged, processed, and excreted. In the other quarter — the ones carrying certain HLA-DR/DQ haplotypes — the antigen never gets presented properly, so the body never builds the antibody that would clear it. The biotoxin recirculates. The innate immune system keeps firing. Cytokines stay elevated for years.

That's the whole disease model in one paragraph, and it explains the two things patients always ask:

• "Why is my whole family fine and I'm not?" — genotype.
• "Why didn't I get better after I moved?" — because the inflammatory cascade is now self-sustaining. Leaving the building is necessary and not sufficient.

The step sequence, decoded

Shoemaker's protocol is a strict ladder. Each rung is verified with labs before you climb the next one.

1. Remove the exposure

Non-negotiable and the single most common failure point. ERMI or HERTSMI-2 dust testing on the home, remediation done properly (containment, source removal — not fogging), and honest assessment of the workplace and the car.

If you cannot get out of the building, the rest of the protocol is a treadmill.

2. Bind the biotoxins

Cholestyramine (CSM) is the published binder, with Welchol as the lower-potency alternative for patients who can't tolerate it. In our clinic we frequently begin with combination binders (charcoal / bentonite / chitosan blends) because compliance over a 12-month arc beats potency in a 3-week arc.

Rules that don't change: two hours away from food, medications, and supplements. Start at a fraction of target dose. Escalate over weeks.

3. Eradicate MARCoNS

Multiple Antibiotic Resistant Coagulase Negative Staph colonizes the deep nasal passages in a large share of CIRS patients and keeps MSH suppressed. Confirmed by nasal swab culture, treated with compounded nasal antimicrobials.

4. Correct antigliadin antibodies

Gluten-free for three months, re-test. This step is short, cheap, and frequently skipped.

5. Correct androgens

Testosterone, DHEA, and aromatase behavior normalize for many patients once inflammation drops — Shoemaker's guidance was explicitly to avoid premature hormone replacement here, and that guidance has aged well.

6. Correct ADH / osmolality

The thirst-and-frequent-urination pattern, static shocks, and dehydration-despite-drinking. Treated by addressing the underlying inflammation, occasionally with DDAVP under supervision.

7. Correct MMP-9

Diet-led (low-amylose), plus omega-3s at therapeutic dose. MMP-9 is the marker that tracks how much inflammation is crossing into tissue.

8. Correct VEGF

The capillary hypoperfusion marker — this is the one that maps to "I can't climb a flight of stairs anymore."

9. Correct C3a

When elevated, it points toward Lyme co-infection rather than mold alone. This is the fork in the road where a lot of "mold-only" protocols quietly fail.

10. Correct C4a

The classic biotoxin marker. Slow to fall, and useful precisely because it's slow — it's a real signal of trend, not noise.

11. Correct TGF-β1

Often the last inflammatory marker to normalize, associated with autonomic symptoms and tissue remodeling.

12. VIP replacement

Vasoactive Intestinal Polypeptide, intranasal, as the final restorative step once the building is clean, MARCoNS is gone, and the upstream markers have moved. Used too early it doesn't hold.

The three places patients stall

Stall 1 — the building. Nine times out of ten, a "non-responder" is still sleeping in the exposure. Test the home before you buy another supplement.

Stall 2 — binders before drainage. The published protocol assumes reasonably functional excretion. Many chronically ill patients don't have it. This is where we deviate: two to four weeks of bowel, bile, and lymphatic support before binders, every time. See our Klinghardt mold protocol update for how that sequencing runs.

Stall 3 — co-infections nobody looked for. Elevated C3a, a plateau at 60% recovery, or symptoms that migrate — that's the Lyme/Bartonella/EBV conversation, and it needs a clinician who works in that space.

How we actually run it in 2026

We keep Shoemaker's biomarker spine because it's the only objective scoreboard in this field. We layer on:

• Urinary mycotoxin testing (GPL-MycoTOX or Vibrant) alongside HERTSMI-2, so you're measuring both the body and the building.
• Drainage-first sequencing borrowed from the Klinghardt arc, which dramatically reduces herx severity.
• DNA and epigenetic data to individualize detox-pathway support instead of guessing.
• Nervous-system work in parallel, not at the end — limbic and vagal dysregulation is why some patients stay symptomatic after markers normalize.

If you want to know whether this thread is worth pulling for you, the cheapest honest starting point is a Health Decode — a $47 personalized root-cause report. If you've already run the panel and stalled, that's a Private Concierge case.

Related reading

• Shoemaker vs Klinghardt — two mold protocols compared
• The CIRS lab panel decoded
• VCS and HLA — the two tests that decide if mold is your problem
• Dr. Ritchie Shoemaker — hub

---

Medically reviewed by Dr. Nicole Rivera, Integrative Medicine Practitioner. Last reviewed August 2026. Sources: Shoemaker RC, Surviving Mold (2010) and subsequent Biotoxin Illness diagnostic and treatment protocol updates (2018–2024); Berndtson K, Chronic Inflammatory Response Syndrome (2013); Brewer JH, Thrasher JD, Hooper D, Toxins (2014). This article is educational and is not a diagnosis or a treatment plan. Biotoxin protocols require clinician supervision.